Absci Corporation is a clinical-stage biopharmaceutical company that specializes in using generative artificial intelligence to design and create biologic drugs. The company operates a data-first drug creation platform that integrates AI models with scalable wet lab technologies to discover, optimize, and produce therapeutic proteins and antibodies. Absci’s integrated platform is used to identify novel drug targets, generate and engineer therapeutic candidates, and develop production cell lines in a unified process, aiming to streamline early-stage discovery and development workflows for biologics. Its technology leverages synthetic biology and high-throughput experimentation to predict, design, build, and screen large libraries of biologic drug candidates for partners in the biopharmaceutical industry. Absci focuses today on advancing AI-designed antibody therapeutics and other biologics across multiple disease areas, collaborating with pharmaceutical and biotechnology companies globally. Founded in 2011 and headquartered in Vancouver, Washington, Absci plays a specialized role at the intersection of biotechnology, artificial intelligence, and drug discovery.